It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Glioblastoma (GBM) is the most common and aggressive brain tumor and is associated with poor prognosis. GBM cells are frequently resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and finding new combinatorial therapies to sensitize glioma cells to TRAIL remains an important challenge. PIM kinases are serine/threonine kinases that promote cell survival and proliferation and are highly expressed in different tumors. In this work, we studied the role of PIM kinases as regulators of TRAIL sensitivity in GBM cells. Remarkably, PIM inhibition or knockdown facilitated activation by TRAIL of a TRAIL-R2/DR5-mediated and mitochondria-operated apoptotic pathway in TRAIL-resistant GBM cells. The sensitizing effect of PIM knockdown on TRAIL-induced apoptosis was mediated by enhanced caspase-8 recruitment to and activation at the death-inducing signaling complex (DISC). Interestingly, TRAIL-induced internalization of TRAIL-R2/DR5 was significantly reduced in PIM knockdown cells. Phospho-proteome profiling revealed a decreased phosphorylation of p62/SQSTM1 after PIM knockdown. Our results also showed an interaction between p62/SQSTM1 and the DISC that was reverted after PIM knockdown. In line with this, p62/SQSTM1 ablation increased TRAIL-R2/DR5 levels and facilitated TRAIL-induced caspase-8 activation, revealing an inhibitory role of p62/SQSTM1 in TRAIL-mediated apoptosis in GBM. Conversely, upregulation of TRAIL-R2/DR5 upon PIM inhibition and apoptosis induced by the combination of PIM inhibitor and TRAIL were abrogated by a constitutively phosphorylated p62/SQSTM1S332E mutant. Globally, our data represent the first evidence that PIM kinases regulate TRAIL-induced apoptosis in GBM and identify a specific role of p62/SQSTM1Ser332 phosphorylation in the regulation of the extrinsic apoptosis pathway activated by TRAIL.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 CSIC, CIBERONC, Parque Tecnológico Ciencias de la Salud, Instituto de Parasitología y Biomedicina López-Neyra, Armilla, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846) ; Carlos III Health Institute, Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
2 Carlos III Health Institute, Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427) ; CSIC-Universidad de Sevilla-Universidad Pablo de Olavide, CIBERONC, Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, Sevilla, Spain (GRID:grid.427489.4) (ISNI:0000 0004 0631 1969)
3 CSIC, CIBERONC, Parque Tecnológico Ciencias de la Salud, Instituto de Parasitología y Biomedicina López-Neyra, Armilla, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846)
4 Centro de Investigaciones Biológicas, CSIC, Department of Molecular Biomedicine, Madrid, Spain (GRID:grid.418281.6) (ISNI:0000 0004 1794 0752)
5 HUMV—Hospital Universitario Marqués de Valdecilla Avenida Valdecilla, 25, Santander, Spain (GRID:grid.411325.0) (ISNI:0000 0001 0627 4262)